相关实验视频
Updated: Sep 10, 2025

05:23
Investigating Migraine-Like Behavior Using Light Aversion in Mice
Published on: August 11, 2021
4.0K
对偏头痛抗CGRP治疗的延迟反应
Oreste Marsico1, Marta Lioi2, Michele Trimboli3
1Department of Neuroscience, "Giovanni Paolo II" Hospital, Lamezia Terme, Catanzaro, Italy.
Pain management
|August 21, 2025
概括
许多偏头痛患者从抗素基因相关 (CGRP) 疗法中受益,但有些人反应迟于3个月. 对于这些反应迟到和超迟的患者,需要长达12个月的治疗时间才能获得显著的偏头痛缓解.
科学领域:
- 神经学
- 药理学
- 临床医学
背景情况:
- 偏头痛是一种广泛的神经疾病,
- 现有的预防性治疗通常有效性和耐受性有限.
- 针对素基因相关 (CGRP) 的单克隆抗体提供了新的治疗途径.
研究的目的:
- 审查偏头痛患者对抗CGRP治疗的晚期和超晚期反应的发生情况.
- 探索延迟治疗反应的潜在机制和临床意义.
- 评估是否需要延长治疗时间超过标准的3个月.
主要方法:
- 对相关文献进行了叙述性审查.
- 在PubMed,科学网和谷歌学者中进行了全面的文献搜索.
- 包括到2025年7月发表的研究,重点是真实世界的数据.
主要成果:
- 实践研究表明,很大一部分最初对抗CGRP治疗没有反应的患者在以后的时间获得了临床益处.
- 大约三分之一的不响应者在6个月后得到改善 ("后期响应者"),在12个月后获得进一步的好处 ("超后期响应者").
- 假设涉及抗CGRP相互作用的中央脱敏机制是这些延迟反应的基础.
结论:
- 显著数量的偏头痛患者对抗CGRP疗法的反应延迟或超延迟.
- 抗CGRP治疗的持续时间应延长至3个月以获得这些延迟的益处.
- 为了优化偏头痛管理策略, 需要进一步研究延迟反应的机制.
相关概念视频
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
259
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
259
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
400
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
400
Myasthenia Gravis: Overview and Treatment
1.9K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.9K
Indirect-Acting Cholinergic Agonists: Pharmacological Actions
828
Indirect-acting cholinergic agonists, also known as anticholinesterases, exert their pharmacological effects by enhancing cholinergic transmission in various body parts, including the neuromuscular junction, autonomic cholinergic synapses, and the brain.
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
828
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
321
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
321
Parkinson's Disease: Treatment
377
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
377

